Resolution of the Expert Council “New approaches to the treatment of axial spondyloarthritis”

On 30 May, 2024, an expert meeting was held to update the approaches for the treatment of axial spondyloarthritis (axSpA). A new approach to the treatment of axSpA was considered, which consists of depleting autoreactive TRBV9+ T- lymphocytes by introducing a monoclonal antibody – the drug seniprutu...

Full description

Saved in:
Bibliographic Details
Main Authors: A. M. Lila, V. I. Mazurov, E. L. Nasonov, S. A. Lukyanov, T. V. Dubinina, I. Z. Gaidukova, A. A. Klimenko, S. A. Lapshina, G. V. Lukina, M. A. Korolev, R. O. Dreval, P. I. Pchelnikova, N. V. Shatalova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2024-06-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/1600
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On 30 May, 2024, an expert meeting was held to update the approaches for the treatment of axial spondyloarthritis (axSpA). A new approach to the treatment of axSpA was considered, which consists of depleting autoreactive TRBV9+ T- lymphocytes by introducing a monoclonal antibody – the drug seniprutug. The value of the drug seniprutug in the treatment of the disease was discussed and key aspects for the incorporation of the drug seniprutug into real-world clinical rheumatological practice were agreed.
ISSN:1996-7012
2310-158X